First-Line Osimertinib Effective Regardless of PD-L1 Expression in EGFR-Mutated NSCLC

An analysis of the phase 3 FLAURA trial demonstrated that osimertinib efficacy was not affected by PD-L1 tumor expression.

from Latest articles from Cancer Therapy Advisor News https://ift.tt/2Of8jt4